EVH:NYSEEvolent Health, Inc Analysis

Evolent Health (EVH) is trading at $3.90, comfortably above its short‑term support of $3.56 but still well below the 200‑day SMA of $5.02, indicating a long‑term downtrend despite a recent 20‑day SMA crossover that hints at modest upward momentum. The RSI sits at 56, suggesting neither overbought nor oversold conditions, while the MACD histogram remains negative and the signal line is bearish, reinforcing a cautious near‑term outlook. Volatility is elevated at over 70% 30‑day and beta is sub‑market at 0.86, reflecting a stock that can swing sharply yet is less sensitive to broader market moves. Fundamentally, the company posted modest 2.6% YoY revenue growth to $1.89 B and a forward PE of 9.66 versus an industry average of 27.8, signaling a significant valuation discount, but margins are weak (operating margin –2% and profit margin –26%) and leverage is high with a debt‑to‑equity of 248. The Q1 2026 earnings showed a slight revenue miss but a non‑GAAP loss per share of –$0.02, just $0.03 above consensus, while forward EPS is projected positive at $0.40. Analyst sentiment is bullish – 14 analysts rate the stock a “strong buy” with a median target of $6.00, implying ~47% upside. The Fear & Greed Index is in “Extreme Greed” territory, but the decreasing volume trend and high recent drawdown (‑81%) underscore lingering risk. Overall, the stock presents an attractive valuation and growth narrative in the health‑information services niche, tempered by profitability challenges, heavy debt, and technical headwinds.